Clik here to view.
BCF, BREF and TBG Companies Seek Global Financial Support to Establish 1000s...
WASHINGTON Dr. Krishnan Suthanthiran is the Founder and President of the Best Cure Foundation (BCF), a non-profit 501(c)(3) corporation established in Springfield, Virginia, USA, in 2007. He also...
View ArticleClik here to view.
Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease
HEIDELBERG, Germany & CAMBRIDGE, Mass. Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announces...
View ArticleClik here to view.
Novaliq的Vevizye®干眼病药物获得CHMP积极意见
德国海德堡和马萨诸塞州剑桥 (美国商业资讯)– 专注于基于独特EyeSol®无水技术率先开发一流眼科治疗药物的生物制药公司Novaliq宣布，欧洲药品管理局人用药品委员会(CHMP)已通过积极意见，建议在欧盟授予Vevizye®的上市许可。该药用于治疗中度至重度干眼症的成年患者，这些患者在使用泪液替代品治疗后仍未见改善。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Aurion Biotech to Present at the 42nd Congress of the European Society of...
SEATTLE & CAMBRIDGE, Mass. & TOKYO Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it will present...
View ArticleClik here to view.
MedTech Innovator Asia Pacific Names APrevent Top 2024 Innovator in Grand...
LOS ANGELES & SINGAPORE MedTech Innovator, the largest accelerator of medical technology companies in the world, in partnership with Asia Pacific Medical Technology Association (APACMed), the...
View ArticleClik here to view.
Aurion Biotech在日本推出用于治疗大疱性角膜病变的Vyznova® (neltependocel)
西雅图、马萨诸塞州剑桥和东京 (美国商业资讯)– Aurion Biotech的使命是通过改变人生的再生疗法恢复数百万患者的视力，公司今天宣布开始在日本市售用于治疗大疱性角膜病变的Vyznova®（通用名称：neltependocel）。公司相信，这是第一种获批用于治疗角膜内皮疾病的细胞疗法；它已在日本获得监管和报销批准。伴随此次商业发布，日本京都府立医科大学(KPUM)的Shigeru...
View ArticleClik here to view.
Aurion Biotech Launches Vyznova® (neltependocel) in Japan for the Treatment...
SEATTLE & CAMBRIDGE, Mass. & TOKYO Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced the commercial launch...
View ArticleClik here to view.
Dopavision Presented Key Data From Its MyopiaX-1 Clinical Trial at the 19th...
BERLIN Dopavision presented the primary 6-month clinical data from its proof-of-concept study of MyopiaX, a transformative approach that aims to control juvenile-onset myopia, on Friday, September...
View ArticleClik here to view.
Novaliq and Laboratoires Théa Announce Partnership and EU Approval for...
HEIDELBERG, Germany & CAMBRIDGE, Mass. & CLERMONT-FERRAND, France Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol®...
View ArticleClik here to view.
Novaliq和Laboratoires Théa宣布建立合作伙伴关系并获得Vevizye®(环孢菌素0.1%滴眼液)欧盟批准
德国海德堡、马萨诸塞州坎布里奇和法国克莱蒙特-费朗 (美国商业资讯)– 以独特的EyeSol®无水技术为基础、专注开发一流眼科治疗药物的生物制药公司Novaliq与欧洲领先的独立眼科护理集团Laboratoires Théa (Théa)...
View Article